Epithalon Research and Safety: What the Evidence Shows

Epithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide that has been studied mainly in cells and animals. Human data is limited to a few small studies, and in July 2026 FDA staff concluded that no clinical data support its safety in people, particularly by subcutaneous injection. It is not an FDA-approved drug. For readers who want a licensed route to peptide-type care, the useful question is who prescribes, which pharmacy compounds, and what evidence sits behind the specific therapy.
VivoChoose Peptide Care With Medical OversightVivo offers provider-supervised, personalized treatment selection and therapies compounded by licensed U.S. pharmacies, delivered directly to your door.VisitTL;DR
- Epithalon is a synthetic peptide developed from epithalamin, a pineal-gland extract. Researchers have reported effects on telomerase, melatonin and circadian genes, mostly in cell and animal work.
- Human evidence consists of small biomarker studies and one older retinitis pigmentosa study. No adequately powered randomized trial has established that it works.
- FDA’s July 2026 briefing found no clinical data supporting safety in humans, and raised concerns about immunogenicity, impurities and a theoretical cancer risk.
- Doses in published studies are research protocols, not personal-use guidance.
- Therapies that are prescribed, compounded by licensed U.S. pharmacies and overseen by a provider carry a different accountability structure than research-chemical products.
Table of Contents
- What Epithalon is
- Preclinical research: cells and animals
- Human evidence: what exists
- What FDA found in 2026
- Dosing: why study protocols are not personal-use guidance
- How to judge safety and effectiveness claims
- What a licensed pathway looks like
- Prescription options with a provider behind them
- FAQ
- Sources
What Epithalon is
Epithalon is a tetrapeptide, a chain of four amino acids (alanine, glutamic acid, aspartic acid and glycine). It was designed from the amino acid makeup of epithalamin, a polypeptide extract from the pineal gland, a small brain structure that helps regulate sleep-wake rhythm. According to a 2026 narrative review in PMC, epithalamin and the synthetic peptide are chemically distinct, and the synthetic version is biologically active but clinically unproven.

The same review lists the areas researchers have examined: telomere maintenance (telomerase activation and telomere elongation), circadian and neuroendocrine function, melatonin synthesis, oxidative stress and markers of cellular aging. Telomeres are the protective caps at the ends of chromosomes that shorten as cells divide. Telomerase is the enzyme that can rebuild them.
The distinction between epithalamin and epithalon matters whenever you read a headline. Several of the longest-running results people cite come from epithalamin, the extract, not the synthetic peptide sold today under the Epithalon name.
Preclinical research: cells and animals
Preclinical means studies done in cell cultures or animals, before or instead of human testing. Results here show biological activity. They do not show what happens in a person.
Cell studies. The review reports that Khavinson and colleagues observed telomerase activity and telomere elongation in human fetal fibroblasts, and cell proliferation beyond the Hayflick limit (the usual ceiling on how many times a normal cell divides) in aging fibroblasts. It also notes a 2025 independent study that reported telomere elongation in human cell models.
Animal studies. In SHR mice, the review describes a 12% increase in maximum lifespan with no change in average lifespan. Other animal work looked at tumor-bearing mice, where some reports describe reduced tumor burden. A lab result like this is not a reason to apply the same logic to people, and it is the reason the cancer question below is treated carefully.
Independence. The Alzheimer’s Discovery Institute’s evidence summary on epithalamin and epithalon states that the preclinical and clinical studies it reviewed were conducted by Dr. Khavinson’s group in Russia, without independent confirmation. It also states there is no evidence from animal or human studies that either substance is neuroprotective, and that neither has been tested for preventing or treating dementia.
Human evidence: what exists
The human literature is small. The 2026 review identifies three categories.
| Study | Substance and route | What was measured | Limits |
|---|---|---|---|
| Night-shift women, 2021 | Sublingual AEDG (epithalon) 0.5 mg per day for 20 days | Melatonin metabolites and circadian gene expression | Small, biomarker outcomes only |
| Retinitis pigmentosa study | 5.0 µg per eye by parabulbar injection (next to the eye) daily for 10 days | Retinal function, visual acuity, visual fields | Randomization and blinding not clearly described |
| Older adults, Korkushko et al., 2006 | Epithalamin (the extract), intramuscular | Mortality over 12 years | Extract, not synthetic peptide; not independently validated |
In the 2021 circadian-gene study, 75 night-shift women were screened and 40 with reduced melatonin-forming function were randomized to sublingual epithalon or saline. Melatonin is the hormone that signals night to the body, which explains why researchers chose this group. The outcomes were biological markers, not health results such as sleep quality or disease risk. Melatonin itself is studied in other settings, for example melatonin and bone density after menopause, and those findings do not carry over to epithalon.
The retinitis pigmentosa study enrolled 162 patients aged 18 to 72, with a 46-patient control group on conventional therapy. The authors reported a positive effect in about 90% of cases and no adverse effects, according to the PMC review. The review also notes that randomization and blinding were not clearly described, which weakens how much weight the result can bear.
The epithalamin study followed 70 older adults who received injections every six months for three years, then were tracked for nine more years. The Alzheimer’s Discovery Institute summary reports a 28% lower mortality rate and about half the cardiovascular mortality in the treated group. Because the substance was the bovine extract and the result has not been replicated independently, it cannot be read as evidence for the synthetic peptide.
The review’s overall conclusion: no adequately powered randomized trial has established therapeutic efficacy for epitalon, and pharmacokinetic (how the body absorbs and clears it), dose-ranging and long-term safety data remain inadequate.

What FDA found in 2026
FDA’s regulation of compounding explains why this matters. A 503A compounding pharmacy prepares individual prescriptions for named patients. Under FDA’s framework, certain bulk drug substances can be used only if they are on a list of eligible substances, and FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviews candidates for that list.
In the July 2026 PCAC briefing materials, FDA reports the following:
- Two nominations for epitalon were withdrawn by the nominators. FDA then evaluated epitalon free base and epitalon acetate on its own initiative, considering only the nominated use, insomnia.
- Staff concluded there are no clinical data supporting the safety of either form in humans, particularly by the proposed subcutaneous route. The nominated products were 10 mg/mL and 3000 mcg/mL subcutaneous formulations.
- The balance of criteria weighed against adding either substance to the 503A bulks list for insomnia.
- Epitalon free base was found to be not well characterized physically and chemically. FDA cited inconsistent naming and inadequate data on identity, purity and quality for an injection, and noted that no applicable monograph or approved drug containing epitalon exists.
- For injectables, FDA raised an immunogenicity concern: peptide aggregation and peptide-related impurities can provoke an immune response, and no clinical studies assessing this were provided or identified. It also noted a 2015 analysis that found epitalon in two illegal pharmaceutical preparations.
The PMC review summarizes FDA’s unresolved areas as dose-dependent and organ toxicity, immunogenicity, genotoxicity, reproductive and developmental toxicity, and a mechanistic carcinogenicity concern. The last arises because lengthening telomeres is a feature of many cancer cells, and no two-year carcinogenicity studies exist. A 2025 review cited there adds that drug-drug and food-drug interaction data are missing.
These are statements about missing data, not proven harm. The reported absence of adverse effects in the retinitis pigmentosa study and the older elderly study is real, but the review points out that none of the available studies were designed as dedicated prospective safety studies.
Dosing: why study protocols are not personal-use guidance
Readers often ask how often Epithalon is taken. Published protocols vary widely by route and purpose, as the table above shows: micrograms per eye by injection beside the eye, 0.5 mg sublingually for 20 days, and 10 mg intramuscular injections of the extract. Each was a research protocol, run under investigator oversight, for a specific question and population.
There are three reasons these numbers do not translate into a personal schedule:
- No dose-escalation or pharmacokinetic studies exist, so no one has established how dose relates to exposure or to risk.
- The product matters as much as the number. FDA found that identity, purity and quality data for epitalon injection were inadequate, so a milligram figure on a vial label does not tell you what is in it.
- Route changes everything. FDA’s safety concern was specific to subcutaneous use, while the most-cited human data came from sublingual and eye-adjacent routes.
Dosing for any prescription therapy belongs in a conversation with a licensed provider who has reviewed your history, medications and labs.
How to judge safety and effectiveness claims
A sound way to read any peptide claim is to ask five questions:
- Was it in humans, or in cells and animals? Mouse lifespan and cell telomere results are preclinical.
- Which substance was used? Epithalamin extract and synthetic epitalon are different products.
- Was the outcome a health result or a biomarker? A change in a gene expression marker is not a change in disease risk.
- Was it independently replicated? The Alzheimer’s Discovery Institute reports that it was not, outside one research group.
- Is there a regulatory finding? FDA’s 2026 review is the most recent public regulatory assessment of epitalon.
Products sold online as research chemicals are labeled not for human use, which means no prescriber has reviewed the buyer and no pharmacy has dispensed against a prescription. The Google results for this keyword reflect that split: some pages repeat FDA’s findings, while others describe the peptide only as a research material.
What a licensed pathway looks like
For people who track their health with wearables and lab work, or who are comparing NAD+ and peptide telehealth providers, the structural questions are the same whichever therapy is considered:
- Who prescribes? A licensed provider reviews your history and decides whether a therapy is appropriate. Rules vary by state; our guide on who prescribes peptides in the U.S. covers how location sets them.
- Which pharmacy compounds? A licensed U.S. pharmacy should prepare the medication against your prescription. See what patients should verify about compounding pharmacies.
- What screening and monitoring apply? Our overview of peptide therapy safety, risks and screening lists what a provider should ask before and during treatment.
- How is your health data handled? For telehealth, HIPAA-compliant intake and records matter as much as the product.
This structure separates a prescription therapy from an unregulated vial, and it applies to every therapy a provider supervises.
Our perspective
Epithalon is a good example of why we start with the evidence before the product. The cell and animal findings are interesting, the human data is thin, and FDA’s 2026 review says plainly what is not yet known. Our approach is to hold every therapy to the same standard: a licensed provider reviews your intake, a licensed U.S. pharmacy prepares the prescription, and ongoing supervision continues after the first shipment.
We also think people deserve clear separation between human evidence and preclinical research. When we describe a treatment, we say which kind of data supports it and avoid benefit claims the data does not support. Health privacy belongs in the same conversation, which is why our intake and records follow HIPAA-compliant practices.
For people who came to peptides through longevity podcasts or newsletters, our advice is to begin with the questions in this article. Who prescribes, who compounds and what has actually been studied in people are the questions that decide whether a therapy fits you.
Jack
Prescription options with a provider behind them
If your goal is supervised care rather than a research peptide, Vivo offers prescription therapies compounded by licensed U.S. pharmacies and delivered to your home, with telehealth intake and provider oversight and no in-office visit. A provider reviews each request and approves or declines it. One example is Sermorelin, priced at $135 per month or $339 per quarter. Our Sermorelin side effects guide explains what is common and what to ask a provider. The full range, including NAD+ and glutathione in several formats, is on the Vivo homepage.
FAQ
Is Epithalon FDA approved?
No. FDA’s July 2026 briefing states that no approved drug containing epitalon exists. FDA staff also concluded that the balance of criteria weighed against adding it to the 503A bulks list for the nominated use of insomnia.
Is Epithalon safe?
Safety in humans has not been established. FDA staff found no clinical data supporting safety, and the 2026 PMC review notes there are no dedicated prospective safety, dose-escalation or long-term studies. The small studies that exist reported no adverse effects, but they were not designed to test safety.
Does Epithalon lengthen telomeres in people?
Telomere elongation has been reported in human cell cultures, including by a 2025 independent study. No adequately powered human trial has shown that this translates into a health benefit, and FDA raised a theoretical carcinogenicity concern linked to telomere lengthening.
How often should you take Epithalon?
No established personal-use schedule exists. Published protocols differ by route, dose and duration, such as 0.5 mg sublingually for 20 days in one study and daily eye-adjacent injections for 10 days in another. They were research designs, and dosing decisions belong with a licensed provider.
Can I take Epithalon with other peptides?
Interaction data is missing. The 2025 review cited in the PMC article reports that drug-drug and food-drug interaction data are absent. A provider who knows your full medication list is the right person to ask about combinations.
Sources
- Epitalon and Epithalamin: A Narrative Review (PMC, 2026)
- FDA Pharmacy Compounding Advisory Committee meeting materials, July 2026
- AEDG Peptide Regulates the Expression of Circadian Genes (2021)
- Epithalamin/Epithalon evidence summary, Alzheimer’s Discovery Institute
